Neuron Specific Enolase in Ventricular Assist Device Recipients
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/30/2013 |
| Start Date: | June 2012 |
| Contact: | Peter M Eckman, MD |
| Email: | eckmanp@umn.edu |
| Phone: | 612-626-5320 |
An observational study of neuron specific enolase, as a marker of reperfusion injury, in
LVAD recipients before and following VAD implantation.
Patients eligible for left ventricular assist device (LVAD) typically have severe heart
failure, which is characterized by poor cardiac output. The relatively abrupt increase in
cardiac output that follows implant of a LVAD may cause reperfusion injury. Furthermore,
selected patients may have particularly severe consequences of such injury, including
refractory acidosis and vasoplegia. Neuron specific enolase (NSE) has been established as a
biomarker of reperfusion injury. We hypothesize that changes in NSE following LVAD will be
greater than the changes in NSE noted in a control population of patients undergoing non-VAD
cardiac surgery.
Inclusion Criteria:
Group 1 - Pre-VAD implantation patients
- 18 years and older
- lanning to undergo VAD implantation Group 2 Cardiac Surgery Comparison Group
- 18 years or older
- Planning to undergo valve or coronary bypass surgery
Exclusion Criteria:
- Acute cerebrovascular infarction
We found this trial at
1
site
2450 Riverside Ave
Minneapolis, Minnesota 55454
Minneapolis, Minnesota 55454
(612) 273-3000
University of Minnesota Medical Center, Fairview Improving patients' lives drives the innovation that makes University...
Click here to add this to my saved trials
